Vertex Pharmaceuticals' business will suffer if other drugmakers launch competing cystic fibrosis drugs. Despite this threat, ...
Zacks Investment Research on MSN
Vertex Pharmaceuticals (VRTX) beats stock market upswing: What investors need to know
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $441.20, moving +1.27% from the previous trading session. This move outpaced the S&P 500's daily gain of 1.2%. Meanwhile, the Dow ...
"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.
On April 10, Morgan Stanley raised its price recommendation on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to $612 from ...
As drugmakers strive to fine tune the delivery of their medications for better convenience and patient adherence, Halozyme is putting a recent acquisition in the space to work, thanks to a new tie- | ...
View Vertex Pharmaceuticals Incorporated VRTX stock quote prices, financial information, real-time forecasts, and company news from CNN.
GlobalData on MSN
Halozyme and Vertex sign deal for Hypercon technology
Under the agreement, Vertex will make a $15m upfront payment to Halozyme and potential future milestone payments.
As growth in Vertex's cystic fibrosis portfolio buoys the company amid the launch of gene therapy Casgevy, the company is feeling confident enough to boost its revenue outlook for the year. After ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results